Hidradenitis suppurativa (HS) is a relatively common skin disease, affecting as many as one percent of people worldwide. But ...

Novartis AG (NYSE:NVS ... So, moving to slide eight, Kesimpta continued to see strong demand globally, and it's a unique ...

Operator Good morning and good afternoon, and welcome to the Novartis Q3 2024 results release ... So moving to Slide 8, ...

Swiss pharma giant Novartis AG NVS reported better-than-expected ... driven by the momentum in Entresto, Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus ...

Novartis is scheduled to report results for ... neuroscience medicine Kesimpta and cardiovascular drug Entresto--the patent of which expires in 2025--are expected to be the key drivers in the ...

Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus Estimate of $12.6 billion. Shares of Novartis have risen 14.6% year to date compared with the industry’s ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage ...

Wide-moat Novartis' third-quarter results were modestly ... these three drugs are about 23% of total sales. Kesimpta (a self-administered drug for relapsing forms of multiple sclerosis) grew ...

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali. Novartis released its ...

“We are proud to help redefine CML treatment once again with Scemblix, as we continue to deliver on our 20+ year commitment to innovation and support in CML,” said Victor Bulto, President US, Novartis ...